GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Item 9 Labs Corp (OTCPK:INLB) » Definitions » Piotroski F-Score

Item 9 Labs (Item 9 Labs) Piotroski F-Score : 4 (As of Apr. 30, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Item 9 Labs Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Item 9 Labs has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Item 9 Labs's Piotroski F-Score or its related term are showing as below:

INLB' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 7
Current: 4

During the past 13 years, the highest Piotroski F-Score of Item 9 Labs was 7. The lowest was 2. And the median was 4.


Item 9 Labs Piotroski F-Score Historical Data

The historical data trend for Item 9 Labs's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Item 9 Labs Piotroski F-Score Chart

Item 9 Labs Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 4.00 3.00 4.00 4.00

Item 9 Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 4.00 3.00 2.00 4.00

Competitive Comparison of Item 9 Labs's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Item 9 Labs's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Item 9 Labs's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Item 9 Labs's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Item 9 Labs's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Net Income was -18.449 + -3.258 + -3.417 + -5.911 = $-31.04 Mil.
Cash Flow from Operations was -0.238 + -1.335 + 0.303 + 0.15 = $-1.12 Mil.
Revenue was 4.001 + 5.004 + 5.663 + 5.022 = $19.69 Mil.
Gross Profit was 0.646 + 2.622 + 3.718 + 2.819 = $9.81 Mil.
Average Total Assets from the begining of this year (Jun22)
to the end of this year (Jun23) was
(120.528 + 110.762 + 114.67 + 114.127 + 112.015) / 5 = $114.4204 Mil.
Total Assets at the begining of this year (Jun22) was $120.53 Mil.
Long-Term Debt & Capital Lease Obligation was $0.15 Mil.
Total Current Assets was $3.35 Mil.
Total Current Liabilities was $58.81 Mil.
Net Income was -9.046 + -3.345 + -3.878 + -5.47 = $-21.74 Mil.

Revenue was 6.094 + 6.186 + 6.638 + 4.931 = $23.85 Mil.
Gross Profit was 1.301 + 2.399 + 2.677 + 1.59 = $7.97 Mil.
Average Total Assets from the begining of last year (Jun21)
to the end of last year (Jun22) was
(149.923 + 116.809 + 117.021 + 120.874 + 120.528) / 5 = $125.031 Mil.
Total Assets at the begining of last year (Jun21) was $149.92 Mil.
Long-Term Debt & Capital Lease Obligation was $2.21 Mil.
Total Current Assets was $5.69 Mil.
Total Current Liabilities was $39.47 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Item 9 Labs's current Net Income (TTM) was -31.04. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Item 9 Labs's current Cash Flow from Operations (TTM) was -1.12. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun22)
=-31.035/120.528
=-0.25749204

ROA (Last Year)=Net Income/Total Assets (Jun21)
=-21.739/149.923
=-0.1450011

Item 9 Labs's return on assets of this year was -0.25749204. Item 9 Labs's return on assets of last year was -0.1450011. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Item 9 Labs's current Net Income (TTM) was -31.04. Item 9 Labs's current Cash Flow from Operations (TTM) was -1.12. ==> -1.12 > -31.04 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun22 to Jun23
=0.145/114.4204
=0.00126726

Gearing (Last Year: Jun22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun21 to Jun22
=2.205/125.031
=0.01763563

Item 9 Labs's gearing of this year was 0.00126726. Item 9 Labs's gearing of last year was 0.01763563. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun23)=Total Current Assets/Total Current Liabilities
=3.347/58.813
=0.05690919

Current Ratio (Last Year: Jun22)=Total Current Assets/Total Current Liabilities
=5.692/39.47
=0.14421079

Item 9 Labs's current ratio of this year was 0.05690919. Item 9 Labs's current ratio of last year was 0.14421079. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Item 9 Labs's number of shares in issue this year was 101.84. Item 9 Labs's number of shares in issue last year was 96.163. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=9.805/19.69
=0.49796851

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=7.967/23.849
=0.33406013

Item 9 Labs's gross margin of this year was 0.49796851. Item 9 Labs's gross margin of last year was 0.33406013. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun22)
=19.69/120.528
=0.16336453

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun21)
=23.849/149.923
=0.15907499

Item 9 Labs's asset turnover of this year was 0.16336453. Item 9 Labs's asset turnover of last year was 0.15907499. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Item 9 Labs has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Item 9 Labs  (OTCPK:INLB) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Item 9 Labs Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Item 9 Labs's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Item 9 Labs (Item 9 Labs) Business Description

Traded in Other Exchanges
N/A
Address
2111 E. Highland Avenue, Suite B375, Phoenix, AZ, USA, 85016
Item 9 Labs Corp is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The company also offers a dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. It also brings industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation.
Executives
Taylor Lawrence X. Iii director 2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Eric Kutscher director 2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Michael P Keskey director C/O ITEM 9 LABS, 2727 N. 3RD STREET, SUITE 201, PHOENIX AZ 85004
Douglas P Bowden director C/O ITEM 9 LABS 2727 N. 3RD STREET., SUITE 201, PHOENIX AZ 85004
Christopher Leland Wolven officer: Chief Operating Officer 5743 N 19TH ST, PHOENIX AZ 85016
Sara Gullickson director, officer: Chief Executive Officer 1709 BETHANY RD, PHOENIX AZ 85016
Andrew Douglas Bowden director 3621 N 39TH ST, PHOENIX AZ 85018
Robert E Mikkelsen officer: CFO, Secretary, Treasurer 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Patrick Sean Dugan 10 percent owner 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Andrew Poirier 10 percent owner 1946 E RANCHO DR, PHOENIX AZ 85016
Bryce Skalla director, officer: President 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Cohen Daniel E Md director, officer: President 10035 GRISTMILL RIDGE, EDEN PRAIRIE MN 55347
Hayjour Family Limited Partnership director, officer: President & CEO 10799 N 90TH STREET, SUITE 200, SCOTTSDALE AZ 85260
Jessica L Smith officer: CFO, Secretary, Treasurer 8399 E. INDIAN SCHOOL RD., SUITE 202, SCOTTSDALE AZ 85251
Lorrie Henderson officer: Chief Operating Officer 8399 E INDIAN SCHOOL RD, SUITE 202, SCOTTSDALE AZ 85251